Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories
-
REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Regenxbio Inc. (RGNX) PT Lowered to $90 at Chardan Capital Markets
-
REGENXBIO to Participate in Upcoming Investor Conferences
-
REGENXBIO To Present at the Chardan 5th Annual Genetic Medicines Manufacturing Summit
-
REGENXBIO to Participate in Upcoming Investor Conferences
-
Regenxbio Inc. (RGNX) PT Lowered to $100 at Chardan Capital Markets, Following Drug Trial Update
-
Buy Regenxbio (RGNX) for Breakup Story - Chardan Capital Markets
-
REGENXBIO to Present at The Chardan 3rd Annual Genetic Medicines Conference
-
Regenxbio Inc. (RGNX) PT Raised to $145 at Chardan Capital Markets
-
Pre-Open Stock Movers 02/25: (ONCE) (CMTA) (QURE) Higher; (MDR) (CRON) (NBR) Lower (more...)
-
REGENXBIO to Present at the Chardan 2nd Annual Genetic Medicines Conference
-
Regenxbio Inc. (RGNX) PT Lowered to $127.50 at Chardan Capital Markets; Sees Low Bar in Wet AMD
-
Regenxbio Inc. (RGNX) PT Raised to 'Street High' $130 at Chardan Capital Markets
-
Regenxbio Inc. (RGNX) PT Raised to $90 at Chardan Capital Markets on Novartis-AveXis; Could Also Become a Target
-
Regenxbio Inc. (RGNX) PT Raised to $85 at Chardan Capital Markets
-
REGENXBIO to Present at Upcoming Investor Conferences
-
Regenxbio Inc. (RGNX) PT Raised to $75 at Chardan Capital Markets
-
REGENXBIO Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
-
Regenxbio Inc. (RGNX) PT Raised to $50 at Chardan Capital Markets on News Dr. Olivier Danos is New CSO; 'Watershed Moment'
-
Regenxbio (RGNX) Reports Pricing of 3.7M Share Offering at $20.50
-
REGENXBIO Announces Pricing of Public Offering of Common Stock
-
Regenxbio (RGNX) Plans $75M Common Stock Offering
-
REGENXBIO Announces Proposed Public Offering of Common Stock
-
Chardan Capital Lifts PT on REGENXBIO (RGNX) to $35 Amid New FDA RPD Designation for RGX-111
-
Chardan Capital Markets Starts Regenxbio Inc. (RGNX) at Buy
-
REGENXBIO Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
REGENXBIO Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
REGENXBIO (RGNX) IPO Opens Up 38%
-
REGENXBIO (RGNX) IPO Prices In-Line at $22
-
REGENXBIO Announces Pricing of Initial Public Offering
-
REGENXBIO Announces Pricing of Initial Public Offering
-
REGENXBIO (RGNX) Sees IPO Price of $17 - $19/Share
-
REGENXBIO (RGNX) Files for $100M Common Stock IPO
